Want to see PYXS full AI Analyst Report?
Top Page
Pyxis Oncology
(NASDAQ:PYXS)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.50
▼(-18.30% Downside)
Action:Reiterated
Date:10/01/26
The score is held down primarily by weak financial performance (large ongoing losses, significant cash burn, and a weakened balance sheet with increased leverage) and a bearish technical trend (price below key moving averages and negative MACD). Offsetting factors include constructive corporate catalysts—promising MICVO clinical data and a meaningful capital raise that extends runway—while valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Promising MICVO clinical efficacy
Updated Phase 1 results provide clinically meaningful support for MICVO’s development path: a 36% confirmed response rate, 94% disease control and 6.2-month median progression-free survival. If durable in later studies, this profile could support differentiation and pivotal-trial execution.
Negative Factors
Large ongoing operating losses
Very large operating and net losses show that Pyxis has not yet converted its clinical pipeline into sustainable profitability. This cost structure can require continued external funding and leaves earnings highly dependent on successful development, partnerships, or eventual commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Promising MICVO clinical efficacy
Updated Phase 1 results provide clinically meaningful support for MICVO’s development path: a 36% confirmed response rate, 94% disease control and 6.2-month median progression-free survival. If durable in later studies, this profile could support differentiation and pivotal-trial execution.
Read all positive factors
Pyxis Oncology Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how the company’s sales are split across business lines and markets—such as product sales, licensing and milestone payments, services or partnerships, and geographic regions—highlighting which areas drive growth and cash flow. A heavy concentration in one product or partner raises revenue risk and volatility, while diversified or recurring streams point to more stable, scalable upside. For smaller or clinical-stage biotech firms, low commercial revenue and reliance on milestone/license payments warn that future earnings depend on clinical progress and deal-making.
Shows how the company’s sales are split across business lines and markets—such as product sales, licensing and milestone payments, services or partnerships, and geographic regions—highlighting which areas drive growth and cash flow. A heavy concentration in one product or partner raises revenue risk and volatility, while diversified or recurring streams point to more stable, scalable upside. For smaller or clinical-stage biotech firms, low commercial revenue and reliance on milestone/license payments warn that future earnings depend on clinical progress and deal-making.
Data provided by:
The Fly
The FlyPyxis Oncology (PYXS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$242.50M
Dividend YieldN/A
Average Volume (3M)1.23M
Price to Earnings (P/E)―
Beta (1Y)1.61
Revenue Growth291.42%
EPS Growth11.70%
CountryUS
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.41
Shares Outstanding119,455,970
10 Day Avg. Volume1,903,907
30 Day Avg. Volume1,232,489
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.34
Price to Sales (P/S)5.16
P/FCF Ratio-1.13
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue15.94
Enterprise Value/Gross Profit15.98
Enterprise Value/Ebitda-2.11
Forecast
1Y Price Target
$9.00Price Target Upside194.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.22
Revenue Forecast (FY)$57.14K
Pyxis Oncology Business Overview & Revenue Model
Company Description
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobu...
How the Company Makes Money
Pyxis Oncology is a clinical-stage biopharmaceutical company and, based on publicly available information, it has not been consistently generating recurring product revenue from marketed drugs. As a result, its revenue (when present) is typically ...
Pyxis Oncology Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
30
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.04M | 13.86M | 16.15M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 11.01M | 11.47M | 15.67M | 0.00 | 0.00 | 0.00 |
| EBITDA | -83.44M | -73.72M | -65.51M | -71.86M | -120.01M | -75.33M |
| Net Income | -88.73M | -79.62M | -77.33M | -73.79M | -120.72M | -75.97M |
Balance Sheet | ||||||
| Total Assets | 54.92M | 91.52M | 157.18M | 173.73M | 211.38M | 280.02M |
| Cash, Cash Equivalents and Short-Term Investments | 33.00M | 66.86M | 126.93M | 119.30M | 179.29M | 274.74M |
| Total Debt | 17.83M | 18.67M | 20.20M | 21.33M | 18.92M | 165.00K |
| Total Liabilities | 43.48M | 38.11M | 36.43M | 48.02M | 50.55M | 18.71M |
| Stockholders Equity | 11.44M | 53.41M | 120.75M | 125.70M | 160.82M | 261.31M |
Cash Flow | ||||||
| Free Cash Flow | -67.92M | -63.51M | -57.91M | -77.44M | -95.73M | -35.87M |
| Operating Cash Flow | -67.91M | -63.50M | -57.67M | -70.71M | -89.33M | -35.33M |
| Investing Cash Flow | 65.40M | 58.86M | 8.15M | -104.85M | -6.40M | -590.00K |
| Financing Cash Flow | 10.63M | 594.00K | 59.33M | 5.93M | 183.00K | 304.04M |
Pyxis Oncology Technical Analysis
Negative
3.06
Price Trends
3.07
Negative
2.65
Negative
2.13
Negative
Market Momentum
-0.33
Positive
30.30
Neutral
7.35
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PYXS, the sentiment is Negative. The current price of 3.06 is above the 20-day moving average (MA) of 2.76, below the 50-day MA of 3.07, and above the 200-day MA of 2.13, indicating a bearish trend. The MACD of -0.33 indicates Positive momentum. The RSI at 30.30 is Neutral, neither overbought nor oversold. The STOCH value of 7.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PYXS.
Pyxis Oncology Risk Analysis
Pyxis Oncology disclosed 77 risk factors in its most recent earnings report. Pyxis Oncology reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pyxis Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $689.44M | -16.12 | -169.47% | ― | ― | -13.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $242.50M | -1.44 | -215.23% | ― | 291.42% | 11.70% | |
46 Neutral | $161.16M | -1.43 | -39.64% | ― | ― | -6.70% | |
42 Neutral | $49.67M | -0.89 | -1266.43% | ― | ― | 49.43% | |
42 Neutral | $102.93M | -2.86 | -171.19% | ― | ― | 83.55% |
* Healthcare Sector Average
PYXS
Pyxis Oncology
2.03
-1.42
-41.16%
NKTX
Nkarta
2.25
>-0.01
-0.44%
GLSI
Greenwich LifeSciences
16.53
6.23
60.49%
ELTX
Elicio Therapeutics
1.89
-8.76
-82.25%
BMEA
Biomea Fusion
1.42
-0.23
-13.94%
NVCT
Nuvectis Pharma
21.12
14.93
241.20%
Pyxis Oncology Corporate Events
Business Operations and StrategyProduct-Related Announcements
Pyxis Oncology Reports Promising MICVO Phase 1 Results
Positive
Sep 9, 2026
On September 9, 2026, Pyxis Oncology reported updated Phase 1 monotherapy data for MICVO in second-line and beyond recurrent or metastatic head and neck squamous cell carcinoma, based on an August 18, 2026 cutoff. At a 5.4 mg/kg capped dose, MICVO...
Business Operations and StrategyExecutive/Board Changes
Pyxis Oncology Elevates Thomas Civik to Permanent CEO
Positive
Sep 8, 2026
On September 4, 2026, Pyxis Oncology’s board appointed interim chief executive Thomas Civik as permanent CEO and simultaneously named him chairman, consolidating leadership as the company advances its lead oncology candidate MICVO through ke...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Pyxis Oncology Raises Capital Through Private Placement Financing
Positive
Jul 2, 2026
Pyxis Oncology entered into definitive securities purchase agreements on June 30, 2026 for a private placement of 19,600,153 shares of common stock at $2.551 per share and accompanying warrants to buy an equal number of shares at $3.289, led by BV...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.